ClinicalTrials.gg
CompletedNCT04428788Updated Dec 22, 2025

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 interventional study of CC-94676 and CC1083611 in Prostatic Neoplasms, sponsored by Celgene. Completed at 19 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
131
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb — 2 open to participants now, 3 under way, 1 of them phase 3. Prostatic Neoplasms · Bristol-Myers Squibb.

Enrollment
11th of 29
131 · median 94
Started
2020
with 1 other
Phase 1
10 of 30
1 open now
Registered
26th of 30
by date

Among the 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb, this one is the 11th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2020, is one of 10 in phase 1, and was the 26th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

03

Conditions studied

  • Prostatic Neoplasms

Keywords

  • Prostate Cancer
  • CC-94676
  • Castration-resistant prostate cancer
  • Adenocarcinoma of the prostate
  • Prostatic Neoplasms Castration-Resistant
  • Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have or cytologically confirmed adenocarcinoma of the prostate
  • Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
  • (ECOG) performance status (PS) 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with an androgen receptor (AR) degrader
  • Concurrent (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP
  • venous thromboembolism within 3 months prior to the first dose of IP
  • Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Administration of CC-94676, CC1083611, and CC1083610

    Drug: CC-94676 · Drug: CC1083611 · Drug: CC1083610

Interventions

  • Specified dose on specified days

    Also known as: BMS-986365

  • DrugCC1083611

    Specified dose on specified days

    Also known as: BMS-986409

  • DrugCC1083610

    Specified dose on specified days

    Also known as: BMS-986410

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) evaluated using the NCI CTCAE v5.0 criteria

    Time frame: From the time of consent at screening until 28 days after thesubject discontinues study treatment.

  2. Dose-limiting toxicity (DLT)

    Time frame: Up to 35 days

  3. Non-tolerated dose (NTD)

    Time frame: Up to 35 days

  4. Maximum tolerated dose (MTD)

    Time frame: Up to 35 days

Secondary outcomes

  1. Confirmed Prostate Specific Antigen (PSA) decline of ≥ 50% from baseline (PSA50)

    Time frame: Up to approximately 4 years

  2. Objective soft tissue response defined by complete response (CR) or partial response (PR) per Prostate Cancer Clinical Trials Working Group 3 (PCWG3)

    Time frame: Up to approximately 4 years

  3. Duration of response (DOR)

    Time frame: Up to approximately 4 years

  4. Proportion of participants alive and not progressed at 6 months

    Time frame: Up to 6 months after treatment is discontinued

  5. PSA Progression Free Survival (PFS)

    Time frame: Up to approximately 4 years

  6. Radiographic progression free survival (rPFS)

    Time frame: Up to approximately 4 years

  7. Overall survival (OS)

    Time frame: Up to approximately 4 years

  8. Overall Survival (OS) rate summarized using the Kaplan-Meier method for the treated population

    Time frame: Up to approximately 4 years

  9. Pharmacokinetics - Area under the plasma concentration time curve (AUC)

    Time frame: Up to 35 days

  10. Pharmacokinetics - Maximum plasma concentration (Cmax)

    Time frame: Up to 35 days

  11. Pharmacokinetics - Time to Cmax (Tmax)

    Time frame: Up to 35 days

07

Study locations

19 sites
  • Local Institution - 116
    Stanford, California 94305-5826, United States
  • Local Institution - 122
    Washington D.C., District of Columbia 20010, United States
  • Local Institution - 103
    Sarasota, Florida 34232, United States
  • Local Institution - 121
    Thomasville, Georgia 31792, United States
  • Local Institution - 108
    Baltimore, Maryland 21287, United States
  • Local Institution - 104
    Boston, Massachusetts 02215, United States
  • Local Institution - 117
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 102
    Grand Rapids, Michigan 49546, United States
  • Local Institution - 112
    New York, New York 10029, United States
  • Local Institution - 109
    New York, New York 10032, United States
  • Local Institution - 105
    New York, New York 10065, United States
  • Local Institution - 106
    Durham, North Carolina 27710, United States
  • Local Institution - 120
    Allentown, Pennsylvania 18103, United States
  • Local Institution - 113
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 107
    Dallas, Texas 75235, United States
  • Local Institution - 119
    Houston, Texas 77030, United States
  • Local Institution - 101
    San Antonio, Texas 78229, United States
  • Local Institution - 115
    Seattle, Washington 98109, United States
  • Local Institution - 111
    Madison, Wisconsin 53792, United States
08

References and documents

Publications

  • Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, Srinivas S, Aparicio A, Narayan V, Runcie KD, Emamekhoo H, Reichert ZR, Nguyen MH, Wells AL, Kandimalla R, Liu C, Suryawanshi S, Han J, Wu J, Arora VK, Pourdehnad M, Armstrong AJ. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025 Jan;36(1):76-88. doi: 10.1016/j.annonc.2024.09.005. Epub 2024 Sep 16. PubMed 39293515 ↗

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.celgene.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Oct 2025, 64 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 64 months is above that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2020
First posted
Jun 11, 2020
StartActual
Jun 22, 2020
Primary completionActual
Oct 28, 2025
CompletionActual
Oct 28, 2025
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04428788
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Jun 22, 2020
Primary completion
Oct 28, 2025
Completion
Oct 28, 2025
Last update
Dec 22, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dezandrodeg

Start the discussion